May 27, 2020
Sierra Oncology Announces Presentations at Upcoming Investor Conferences
May 26, 2020
Sierra Oncology Appoints Dr. Stephen Dilly as President and Chief Executive Officer
May 07, 2020
Sierra Oncology to Hold KOL Call to Discuss Anemia & Transfusion Dependency as Critical Unmet Needs in Myelofibrosis
Feb 26, 2020
Sierra Oncology to Hold Year End 2019 & 2020 Outlook Analyst & Investor Call
Feb 25, 2020
Sierra Oncology to Present at the Cowen 40th Annual Health Care Conference
Feb 06, 2020
Sierra Oncology Completes Conversion of Preferred to Common Stock and Issues Stock to Gilead
Jan 22, 2020
Sierra Oncology Announces Reverse Stock Split
Dec 02, 2019
Sierra Oncology Announces Investor Event to Discuss Momelotinib Data Being Reported at ASH
Nov 20, 2019
Sierra Oncology Launches the MOMENTUM Phase 3 Clinical Trial for Patients with Myelofibrosis
Nov 14, 2019
Sierra Oncology to Present at the Jefferies 2019 London Healthcare Conference
Nov 07, 2019
Sierra Oncology and Gilead Sciences Agree on Amendments to Asset Purchase Agreement for Momelotinib
Jun 25, 2019
Global Myelofibrosis Market 2017-2018 & 2019-2026: Celgene's $1.1bn Impact Buy is First of More Deals to Come in 2018 and Beyond
Jun 05, 2019
Sierra Announces Momelotinib Granted FDA Fast Track Designation
Jun 04, 2019
Sierra Announces FDA Regulatory Clarity for Momelotinib & Design of the MOMENTUM Phase 3 Clinical Trial
May 28, 2019
Sierra Oncology to Present Momelotinib and SRA737 Overview at the Jefferies Global Healthcare Conference in New York
Dec 03, 2018
Sierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib
Nov 27, 2018
Sierra Oncology to Host Analyst Call Highlighting Clinical Data on Momelotinib's Anemia Benefit
Aug 22, 2018
Sierra Oncology Acquires Momelotinib, an Investigational Janus Kinase (JAK) 1/2 and Activin Receptor Type 1 (ACVR1) Inhibitor for Myelofibrosis, from Gilead Sciences